Von Eschenbach to resign from National Cancer Institute post

FDA acting commissioner Andrew von Eschenbach said this week he would resign from his other job, as director of the National Cancer Institute (NCI), effective June 10. Von Eschenbach’s holding of both positions had raised questions of a potential conflict of interest. He has led NCI since 2002. Von Eschenbach became acting commissioner in September 2005 and in March was nominated by President Bush to lead the regulatory agency. His confirmation remains “in limbo” amid debate on the FDA’s position on the OTC status of Barr’s emergency contraceptive pill Plan B.
You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.